Plasma levels of catecholamine metabolites predict the response to sulpiride or fluvoxamine in major depression.
We investigated the relationships between the changes in plasma catecholamine metabolites obtained from depressed patients before and after administration of sulpiride, a benzamide compound, or fluvoxamine, a selective serotonin reuptake inhibitor (SSRI), and between clinical responses to treatment with each of these drugs. Responders to sulpiride had significantly lower plasma homovanillic acid (pHVA) levels before administration of sulpiride than did non-responders or controls (responders: 4.5 +/- 3.1 ng/ml, non-responders: 11.1 +/- 5.9 ng/ml, controls: 10.9 +/- 5.3 ng/ml). Positive relationships were observed between changes in pHVA levels and improvement rates in the 17-item Hamilton Depression Rating Scale (Ham-D). In contrast, responders to fluvoxamine had significantly higher plasma free 3-methoxy-4-hydroxyphenylglycol (pMHPG) levels before administration of fluvoxamine than did non-responders or controls (responders: 8.5 +/- 1.8 ng/ml, non-responders: 5.9 +/- 2.I ng/ml, controls: 5.2 +/- 2.9 ng/ml). Negative relationships were observed between changes in pMHPG levels and improvement rates in Ham-D. These results suggest that lower pretreatment pHVA levels and higher pretreatment levels of pMHPG might be predictors of response to sulpiride and fluvoxamine, respectively, and that sulpiride might produce a functional increase in the dopaminergic system, resulting in improvement in some depressive symptoms; fluvoxamine, on the other hand, might produce a functional decrease in the noradrenergic system via serotonergic neurons, resulting in improvement of those symptoms.
Ueda
N
N
Department of Psychiatry, School of Medicine, University of Occupational and Environmental Health, Fukuoka, Japan. EZD04735@nifty.com
Yoshimura
R
R
Shinkai
K
K
Nakamura
J
J
D000328:Adult; D000368:Aged; D018687:Antidepressive Agents, Second-Generation / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D003865:Major Depressive Disorder / Q000097:blood* / Q000188:drug therapy; D018492:Dopamine Antagonists / Q000627:therapeutic use*; D005260:Female; D016666:Fluvoxamine / Q000627:therapeutic use*; D006719:Homovanillic Acid / Q000097:blood*; D006801:Humans; D008297:Male; D008734:Methoxyhydroxyphenylglycol / Q000097:blood*; D008875:Middle Aged; D011569:Psychiatric Status Rating Scales; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*; D013469:Sulpiride / Q000627:therapeutic use*; D016896:Treatment Outcome
D018687:Antidepressive Agents, Second-Generation; D015415:Biomarkers; D018492:Dopamine Antagonists; D016666:Fluvoxamine; D006719:Homovanillic Acid; D008734:Methoxyhydroxyphenylglycol; D017367:Selective Serotonin Reuptake Inhibitors; D013469:Sulpiride